Materials and Methods Human monocyte-derived macrophages were assayed for H20~ release, adherent cell protein, and antitoxoplasma activity as described (1) , except that the number of mononuclear cells plated ranged up to 2 × 106 and in many experiments, the volume of culture medium was increased to 0.5 ml/well after the first day. The test media described in Table I were added on day 4, 5, or 6 and H202 release tested 3 d later.
Results
H202-Releasing Capacity, Cell Shape, and Adherent Cell Protein. Fig. 1 compares the ability of 11 cytokines to enhance the oxidative metabolism of human monocyte-derived macrophages, rIFN% included as a positive control in each experiment, elevated macrophage H~O2-releasing capacity an average of eightfold above that of cells cultured in medium alone. 50% of the maximal stimulation required ~1 × 10 -~2 M rIFN3, (~0.1 U/ml). The non-~, IFNs were tested over a 105-fold range of concentrations, up to 104 antiviral U/ml. Pure nIFNa (a mixture of subtypes) did not enhance H202 release. In contrast to rIFN% nIFNa at > 1,000 U/ml decreased cell spreading and the amount of protein adherent to the coverslips (Table II) , suggesting toxicity. Results were similar with pure rIFNotA, rIFNaD, and rIFNI3, except that rIFNaD had less effect on cell protein and no effect on cell shape.
Partially purified CSF-1 and GM-CSF did not enhance H~O2 release. However, these preparations did interact with the macrophages, as evidenced by marked spreading of the cells and an increase in the adherent cell protein by a factor of 1.25 _4-0.48 (n --3) for CSF-1 (8) and 2.23 + 0.29 (n = 5) for GM-CSF. When Antitoxoplasma Activity. Under the conditions tested, none of the agents except rIFN7 conferred on macrophages the ability to kill T. gondii or to inhibit its intracellular replication (Table III) .
Discussion
Therapy is now feasible with purified products of cloned genes. This heightens interest in the identification of cytokines that augment the antimicrobial activity of host cells. Recent studies establish that IFN7 promotes host cell-mediated inhibition of a variety of nonviral pathogens, such as toxoplasma (1, 19) , leishmania (2), chlamydia (20) , rickettsia (21) , and malaria. 2 However, it is not clear whether other cytokines can also enhance the nonviral antimicrobial activity of human macrophages or its biochemical correlate, their capacity to secrete reactive oxygen intermediates (22) . In the present work we tested individually many of the cytokines that affect macrophages, with special emphasis on non-'), IFNs. Our findings are consistent with earlier studies in which all detectable MAF activity was depleted from unfractionated, polyclonally activated mononuclear cell supernatants by monoclonal antibody to IFN~, (1, 2, 20) . Thus, when tested in vitro in partially or highly purified form and over a wide range of concentrations, the following affected neither the antitoxoplasma activity of human macrophages nor, with one exception, their secretion of H~O2: nIFNo~, rIFNaA, rIFNaD, rIFN/3, CSF-1, GM-CSF, p-CSF, MIF, niL-2, rIL-2, and TNF. MIF-rich preparations increased macrophage H202 secretion above control approximately threefold less than rIFNT. It will be of interest to test the ability of MIF-treated macrophages to kill parasites more susceptible to oxidative injury than toxoplasmas (22) . We have not yet studied the effect of pure MIF or of monoclonal anti-MIF antibodies, and thus have not proven that MIF was the active factor from the T-T hybridoma used here. It also remains to be seen if MAF is associated with the MIF produced by uncloned, nontransformed lymphocytes. Further study of MIF is underway.
Thus far, IFN~, appears to be the only known host-derived substance with the ability to activate both the oxidative metabolism and antitoxoplasma activity of human macrophages.
Summary
Cytokines affecting mononuclear phagocytes were screened for activation of human macrophages to secrete H~O2 and kill toxoplasmas. In contrast to recombinant interferon-3, (rIFN~), the following factors, tested in partially or highly purified form and over a wide range of concentrations, did not augment these functions: native interferon-~ (nIFNa), rIFNaA, rIFNaD, rIFN/3, colony stimulating factor (type 1) (CSF-1), CSF for granulocytes and macrophages (GM-CSF), pluripotent CSF (p-CSF), tumor necrosis factor (TNF), native interleukin 2 (niL-2), and rIL-2. Partially purified migration inhibitory factor (MIF) enhanced H202-releasing capacity submaximally without inducing antitoxoplasma activity, and warrants further study.
